Full-Time

Regulatory Affairs Specialist II

Posted on 3/12/2025

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Develops medical devices for vascular conditions

Compensation Overview

$86k - $116kAnnually

Junior, Mid

Company Historically Provides H1B Sponsorship

Alameda, CA, USA

Hybrid position requiring some in-office days.

Category
Legal
Risk & Compliance
Legal & Compliance
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor's degree in science discipline or related field with 2+ years of experience, or equivalent combination of education and/or demonstrated experience
  • Proven ability to use and apply technical standards, theories, concepts, and techniques
  • Strong oral, written, and interpersonal communication skills
  • High degree of accuracy and attention to detail
  • Proficient in Word, Excel, PowerPoint, and other computer tools
  • Excellent organizational skills with ability to prioritize assignments while handling various projects simultaneously
Responsibilities
  • Assist in preparing moderately complex submissions to gain approvals such as: 510(k), CE-Mark Technical Dossier, UKCA Mark, other regional Regulatory submissions, IDE, International Clinical Trial Submission, Shonin, and Certificates to Foreign Government
  • Track multiple device projects concurrently [e.g., Design Control, post market activities, Device submission projects]
  • Ensure that regulatory documentation is maintained per internal procedures
  • Research and obtain information on Regulatory Intelligence such as competitor product information and approvals, new or updated regulations/guidance, as directed
  • Communicate and exchange accurate information with all stakeholders (i.e., project teams, health authorities, RA personnel, and management)
  • Support labeling reviews (e.g., Instructions for Use and product labels)
  • Understand the Quality System regulations (ISO 13485), Design Control, and regional Regulatory requirements
  • Assist in various regulatory support activities (e.g. internal/external audits, Field Corrective Actions, FOIAs)
  • Perform other Regulatory department-related duties as assigned
Desired Qualifications
  • Regulatory Medical Device experience preferred

Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products, such as the Penumbra System and the Indigo System, are designed to assist healthcare professionals in addressing issues like stroke and other vascular diseases. These devices work by providing advanced tools for procedures in neurology and vascular surgery, helping to improve patient outcomes. Unlike many competitors, Penumbra focuses specifically on these specialized areas, ensuring their products are tailored to the unique needs of medical professionals in these fields. The company's goal is to enhance the effectiveness of medical treatments through continuous research and development, ultimately improving healthcare delivery across hospitals and clinics in Europe and the Americas.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for minimally invasive procedures boosts Penumbra's market potential.
  • Global neurovascular devices market is projected to grow at 8.5% CAGR until 2030.
  • Technological advancements enhance effectiveness of Penumbra's neurovascular treatments.

What critics are saying

  • Leadership gap due to Don Kassing's retirement may affect strategic decisions.
  • Costa Rica manufacturing expansion could face operational challenges and increased costs.
  • Layoffs in Immersive Healthcare division indicate potential strategic instability.

What makes Penumbra Inc unique

  • Penumbra specializes in neurovascular and peripheral vascular medical devices.
  • The company offers innovative solutions for stroke and neurovascular disease treatment.
  • Penumbra's global presence spans North America, Europe, Asia, and Australia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Neuro News International
Feb 28th, 2025
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access

Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.

Penumbrainc
Feb 27th, 2025
Penumbra Launches ACCESS25[TM] Delivery Microcatheter Designed for Aneurysm Access and Delivery of Elevated Clinical Benefits

Penumbra recently launched the ACCESS25 Delivery Microcatheter, a single lumen medical device designed to aid physicians in accessing the neurovasculature for the delivery of Penumbra's advanced .020" coil platform.

PR Newswire
Feb 21st, 2025
Penumbra, Inc. Announces Don Kassing Will Retire From Board Of Directors

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University

Investing.com
Feb 19th, 2025
UBS raises Penumbra stock price target to $320, keeps buy rating

Penumbra plans to expand its manufacturing capacity with a new facility in Costa Rica.

PR Newswire
Feb 18th, 2025
Penumbra, Inc. Reports Fourth Quarter And Full Year 2024 Financial Results

ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023. Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023